Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar Mar-2016 Mar-2015 Mar-2014 Mar-2013
Growth matrix (%)        
Revenue growth (13) (47) 5.44 36.60
Op profit growth (103) (177) 1.60 20.60
EBIT growth (111) 42.40 (9.10) 25
Net profit growth (327) 340 (65) 115
Profitability ratios (%)        
OPM 0.61 (18) 12.30 12.80
EBIT margin (2.80) 22.90 8.47 9.83
Net profit margin (16) 6.32 0.76 2.25
RoCE 34 (29) 78.10 45.40
RoNW (5.40) 2.20 0.51 1.51
RoA (2.40) 0.94 0.20 0.60
Per share ratios ()        
EPS -- 3.33 0.77 2.05
Dividend per share -- -- -- 0.60
Cash EPS (10) 0.10 (4.10) (2.30)
Book value per share 31 38.50 36.90 36.20
Valuation ratios        
P/E -- 8.92 22.10 18.70
P/CEPS (3) 289 (4.20) (17)
P/B 0.97 0.77 0.46 1.06
EV/EBIDTA 53.50 4.28 5.55 5.90
Payout (%)        
Dividend payout -- -- -- 32.80
Tax payout (1.20) 1.71 (42) (28)
Liquidity ratios        
Debtor days 363 348 186 182
Inventory days 69.50 81.30 48.80 47.90
Creditor days (172) (133) (135) (163)
Leverage ratios        
Interest coverage 0.18 (1.70) (1.20) (1.40)
Net debt / equity 1.35 0.92 1.53 1.17
Net debt / op. profit 151 (3.70) 4.61 3.52
Cost breakup ()        
Material costs (77) (84) (70) (73)
Employee costs (8.20) (11) (7.70) (6.20)
Other costs (14) (23) (10) (7.80)
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar( In .Cr) Mar-2016 Mar-2015 Mar-2014 Mar-2013
Revenue 85.30 97.70 185 176
yoy growth (%) (13) (47) 5.44 36.60
Raw materials (66) (82) (130) (129)
As % of sales 77.40 83.60 69.90 73.20
Employee costs (7) (11) (14) (11)
As % of sales 8.19 11 7.68 6.21
Other costs (12) (23) (19) (14)
As % of sales 13.80 23.40 10.10 7.82
Operating profit 0.52 (18) 22.80 22.50
OPM 0.61 (18) 12.30 12.80
Depreciation (4.90) (6) (9) (8.20)
Interest expense (13) (13) (13) (12)
Other income 1.98 46 1.85 3.04
Profit before tax (15) 8.90 2.49 5.36
Taxes 0.18 0.15 (1) (1.50)
Tax rate (1.20) 1.71 (42) (28)
Minorities and other 1.11 -- -- (0.10)
Adj. profit (14) 9.01 1.40 3.83
Exceptional items -- (2.80) -- 0.13
Net profit (14) 6.18 1.40 3.96
yoy growth (%) (327) 340 (65) 115
NPM (16) 6.32 0.76 2.25
Switch to
Tabular Data
Graph
Y/e 31 Mar ( In .Cr) Mar-2016 Mar-2015 Mar-2014 Mar-2013
Profit before tax (15) 8.90 2.49 5.36
Depreciation (4.90) (6) (9) (8.20)
Tax paid 0.18 0.15 (1) (1.50)
Working capital (1.40) (21) -- 20.50
Other operating items -- -- -- --
Operating cashflow (21) (17) (7.50) 16.10
Capital expenditure (8.70) (8.60) -- 8.62
Free cash flow (30) (26) (7.50) 24.80
Equity raised 98.80 95.70 99 99.10
Investments 16.90 16.90 -- (17)
Debt financing/disposal (5) (32) -- 31.50
Dividends paid -- -- -- 1.12
Other items -- -- -- --
Net in cash 80.70 55.10 91.40 140
Switch to
Tabular Data
Graph
Switch to
Consolidated
Standalone
Y/e 31 Mar ( In .Cr) Mar-2016 Mar-2015 Mar-2014 Mar-2013
Equity capital 18.70 18.70 18.70 21.80
Preference capital -- -- -- --
Reserves 39.10 53.10 50.20 45.70
Net worth 57.80 71.80 68.90 67.50
Minority interest
Debt 80.50 68.70 108 100
Deferred tax liabilities (net) 3.82 4 6.41 5.83
Total liabilities 142 145 184 174
Fixed assets 52.60 54.60 69.30 73
Intangible assets
Investments 16.90 16.90 -- --
Deferred tax asset (net) -- -- -- --
Net working capital 69.70 71.10 112 80.30
Inventories 16.40 16.10 27.40 22.20
Inventory Days 70.10 60.20 54 46.10
Sundry debtors 80.90 88.70 97.50 91.60
Debtor days 346 331 192 190
Other current assets 23.10 20.80 38.80 52.70
Sundry creditors (38) (42) (42) (79)
Creditor days 161 158 82.40 163
Other current liabilities (13) (12) (9.60) (7.60)
Cash 2.71 2.77 2.81 21.10
Total assets 142 145 184 174
Switch to
Consolidated
Standalone


Bafna Pharmaceuticals Ltd Report not showing data